Horita, N., Goto, A., Shibata, Y., Ota, E., Nakashima, K., Nagai, K., & Kaneko, T. (2017). Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev.
Citação norma ChicagoHorita, Nobuyuki, Atsushi Goto, Yuji Shibata, Erika Ota, Kentaro Nakashima, Kenjiro Nagai, and Takeshi Kaneko. "Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease (COPD)." Cochrane Database Syst Rev 2017.
Citação norma MLAHorita, Nobuyuki, et al. "Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease (COPD)." Cochrane Database Syst Rev 2017.